For instance, in melanoma, the variable clinical outcomes following PD-1/PD-L1 blockade can be attributed, in part, to the differential kinetics between genomic mutation acquisition and the final steps of MHC-mediated antigen presentation (Goodman et al., 2017). Here, CD274 is linked to melanoma.